Dutogliptin

Drug Profile

Dutogliptin

Alternative Names: Dutogliptin tartrate; PHX-1149; PHX1149T; REC-01

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Phenomix Corporation
  • Class Antihyperglycaemics; Pyrrolidines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Phase I Myocardial infarction
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 25 Nov 2015 Dutogliptin is in phase I trial for Myocardial infarction in Austria
  • 11 Nov 2015 Recardio plans a phase II trial for Myocardial infarction in Austria
  • 09 Mar 2015 Phase-I clinical trials in Myocardial infarction (In volunteers) in Austria (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top